Sai Parenterals Ltd
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
- Market Cap ₹ 2,142 Cr.
- Current Price ₹ 485
- High / Low ₹ 526 / 400
- Stock P/E 149
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 16.5 %
- ROE 17.1 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
Cons
- Company has high debtors of 283 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 97 | 154 | 163 | |
| 78 | 122 | 124 | |
| Operating Profit | 19 | 32 | 39 |
| OPM % | 19% | 21% | 24% |
| 0 | 1 | 1 | |
| Interest | 6 | 11 | 12 |
| Depreciation | 6 | 9 | 8 |
| Profit before tax | 7 | 13 | 20 |
| Tax % | 40% | 33% | 28% |
| 4 | 8 | 14 | |
| EPS in Rs | 6.13 | 6.36 | 5.43 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 71% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 16% |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|
| Equity Capital | 7 | 13 | 13 | 18 |
| Reserves | 24 | 61 | 80 | 189 |
| 69 | 119 | 94 | 78 | |
| 34 | 75 | 85 | 91 | |
| Total Liabilities | 134 | 268 | 272 | 376 |
| 44 | 70 | 53 | 55 | |
| CWIP | 2 | 0 | 0 | 2 |
| Investments | 0 | 0 | 0 | 0 |
| 88 | 198 | 219 | 320 | |
| Total Assets | 134 | 268 | 272 | 376 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| -13 | -30 | 33 | |
| -19 | -46 | 0 | |
| 24 | 79 | -36 | |
| Net Cash Flow | -8 | 2 | -2 |
| Free Cash Flow | -30 | -72 | 41 |
| CFO/OP | -54% | -94% | 86% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 231 | 302 | 283 |
| Inventory Days | 83 | 143 | 199 |
| Days Payable | 140 | 203 | 225 |
| Cash Conversion Cycle | 174 | 242 | 256 |
| Working Capital Days | 19 | 72 | 79 |
| ROCE % | 16% | 17% |
Documents
Announcements
-
Results-Delay in Financial Results
2d - Sai Parenterals delays results submission to 15 May 2026; audited FY26 results due by 30 May 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting
20 Apr - Board approved up to AUD 1.75 million loan to Sai Singapore Pte. Ltd. on April 20, 2026.
-
Board Meeting Intimation for INTIMATION OF BOARD MEETING WHICH IS PROPOSED TO BE HELD ON 20TH OF APRIL 2026
14 Apr - Board meeting on April 20, 2026 to consider investing in or lending to Noumed Pharmaceuticals Pty Limited.
-
Closure of Trading Window
6 Apr - Trading window closed from April 2, 2026 for Q3 and FY26 results board meeting.
-
Intimation Under Regulation 30(5) Of SEBI
6 Apr - Sai Parenterals appointed three KMPs as authorised persons under Regulation 30(5).
Annual reports
No data available.
Business Profile[1][2]
Sai Parenteral is a diversified pharmaceutical formulations company engaged in R&D, manufacturing, and commercialization of products across both domestic and international markets. Over time, the company has evolved from being a parenteral-focused player into a full-fledged diversified formulations platform, significantly reducing its dependency on injectables in the process.